Alibaba Health's Long-Term Growth Remains Intact -- Market Talk

Dow Jones
05/20

0840 GMT - Alibaba Health Information Technology's long-term growth remains intact despite near-term moderation in profit growth, say UOB Kay Hian's Sunny Chen and Carol Dou in a note. The analysts see structural growth opportunities for the healthcare subsidiary of Alibaba Group, buoyed by sustained innovative-drug momentum, expanding artificial-intelligence adoption, and deeper synergy with the Alibaba ecosystem. They project the company's FY 2026-2028 revenue and adjusted net profit to grow at compound annual growth rates of 12% and 15%, respectively. Still, UOB KH cuts its target price to HK$5.20 from HK$6.00 to reflect faster investment in innovative drugs and AI. The brokerage retains its buy rating. Shares closed 2.0% lower at HK$3.91. (megan.cheah@wsj.com)

 

(END) Dow Jones Newswires

May 20, 2026 04:40 ET (08:40 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10